| High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features JM Rosa-Rosa, T Caniego-Casas, S Leskela, E Cristobal, ... Cancers 11 (1), 74, 2019 | 36 | 2019 |
| Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ … JM Pérez-García, A Llombart-Cussac, M Gion, G Curigliano, ... European Journal of Cancer 148, 382-394, 2021 | 27 | 2021 |
| Use of bevacizumab as a first-line treatment for metastatic breast cancer L Manso, F Moreno, R Márquez, B Castelo, A Arcediano, M Arroyo, ... Current Oncology 22 (2), 51-60, 2015 | 24 | 2015 |
| Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. E Lopez Miranda, A Stathis, D Hess, F Racca, D Quon, J Rodon, ... Journal of Clinical Oncology 39 (15_suppl), 3020-3020, 2021 | 18 | 2021 |
| Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I A Brufsky, D Miles, Z Zvirbule, A Eniu, E Lopez-Miranda, JH Seo, ... Cancer Research 78 (4_Supplement), P5-21-01-P5-21-01, 2018 | 16 | 2018 |
| First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies JM Perez Garcia, J Cortes, A Stathis, R Mous, E López-Miranda, A Azaro, ... J. Clin. Oncol 36, 2018 | 12 | 2018 |
| Strongyloides in bronchoalveolar lavage fluid: practical implications in the COVID-19 era FF Norman, S Chamorro, F Braojos, E López-Miranda, J Chamorro, ... Journal of Travel Medicine 29 (1), taab114, 2022 | 10 | 2022 |
| A phase I study of the pan-notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors GJ Hanna, A Stathis, E Lopez-Miranda, F Racca, D Quon, S Leyvraz, ... Cancer Research Communications 3 (9), 1853-1861, 2023 | 9 | 2023 |
| Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (thelma): a single-arm, multicenter, phase Ib trial E López-Miranda, JM Pérez-García, S Di Cosimo, E Brain, M Ravnik, ... Cancers 12 (12), 3509, 2020 | 9 | 2020 |
| Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study L de la Cruz-Merino, M Gion, J Cruz, JL Alonso-Romero, V Quiroga, ... BMC cancer 22 (1), 1258, 2022 | 6 | 2022 |
| Challenging endocrine sensitivity of hormone receptor-positive/HER2-negative advanced breast cancer with the combination of eribulin and endocrine therapy: The REVERT study A López González, S Del Barco Berrón, I Grau, M Galan, ... Cancers 14 (23), 5880, 2022 | 5 | 2022 |
| Abstract P5-18-07: Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545)±palbociclib in patients with estrogen receptor … TG Neilan, R Villanueva-Vázquez, M Bellet, E López-Miranda, ... Cancer Research 82 (4_Supplement), P5-18-07-P5-18-07, 2022 | 5 | 2022 |
| Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study L De la Cruz-Merino, M Gion, J Cruz-Jurado, V Quiroga, R Andrés, ... Cancers 13 (21), 5432, 2021 | 5 | 2021 |
| Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design M Sampayo-Cordero, B Miguel-Huguet, J Pérez-García, D Páez, ... Contemporary Clinical Trials Communications 20, 100678, 2020 | 4 | 2020 |
| Etirinotecan pegol for the treatment of breast cancer E López-Miranda, J Cortés Expert opinion on pharmacotherapy 17 (5), 727-734, 2016 | 4 | 2016 |
| Discordant humoral and T-cell response to mRNA SARS-coV-2 vaccine and the risk of breakthrough infections in women with breast cancer, receiving cyclin-dependent kinase 4 and 6 … C Saavedra, A Vallejo, F Longo, JJ Serrano, M Fernández, M Gion, ... Cancers 15 (7), 2000, 2023 | 3 | 2023 |
| Effectiveness of olaparib plus trastuzumab in HER2 [+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The … JE Alés-Martínez, S Morales, MF Abad, P Sánchez-Rovira, FJS Bofill, ... Annals of Oncology 30, v139-v140, 2019 | 3 | 2019 |
| Phase Ia/b Study of Giredestrant±Palbociclib and±Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast … KL Jhaveri, M Bellet, NC Turner, S Loi, A Bardia, V Boni, J Sohn, ... Clinical Cancer Research 30 (4), 754-766, 2024 | 2 | 2024 |
| Abstract OT1-01-06: PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts … E López-Miranda, J Gávila, S Pernas, C Saura, M Oliveira, V Serra, ... Cancer Research 77 (4_Supplement), OT1-01-06-OT1-01-06, 2017 | 2 | 2017 |
| Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2 … E López-Miranda, E Brain, C Saura, J Gligorov, C Dubot, V Dieras, ... Cancer Research 77 (4_Supplement), OT1-02-03-OT1-02-03, 2017 | 2 | 2017 |
